208 related articles for article (PubMed ID: 32574083)
1. Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
Sengupta NK; Azizov A; Halder S; Xenodemetropoulos T; Armstrong D; Tse F; Marshall JK; Narula N
Scand J Gastroenterol; 2020 Jul; 55(7):800-805. PubMed ID: 32574083
[No Abstract] [Full Text] [Related]
2. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
[TBL] [Abstract][Full Text] [Related]
3. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
[TBL] [Abstract][Full Text] [Related]
4. Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
Narula N; Lauzon B; Marshall JK
Scand J Gastroenterol; 2019 Jun; 54(6):712-717. PubMed ID: 31144993
[No Abstract] [Full Text] [Related]
5. Long-term safety of vedolizumab for inflammatory bowel disease.
Loftus EV; Feagan BG; Panaccione R; Colombel JF; Sandborn WJ; Sands BE; Danese S; D'Haens G; Rubin DT; Shafran I; Parfionovas A; Rogers R; Lirio RA; Vermeire S
Aliment Pharmacol Ther; 2020 Oct; 52(8):1353-1365. PubMed ID: 32876349
[TBL] [Abstract][Full Text] [Related]
6. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
[TBL] [Abstract][Full Text] [Related]
8. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease.
Al-Bawardy B; Ramos GP; Willrich MAV; Jenkins SM; Park SH; Aniwan S; Schoenoff SA; Bruining DH; Papadakis KA; Raffals L; Tremaine WJ; Loftus EV
Inflamm Bowel Dis; 2019 Feb; 25(3):580-586. PubMed ID: 30165638
[TBL] [Abstract][Full Text] [Related]
10. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
11. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.
Williet N; Boschetti G; Fovet M; Di Bernado T; Claudez P; Del Tedesco E; Jarlot C; Rinaldi L; Berger A; Phelip JM; Flourie B; Nancey S; Paul S; Roblin X
Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1750-1757.e3. PubMed ID: 27890854
[TBL] [Abstract][Full Text] [Related]
12. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.
Guidi L; Pugliese D; Panici Tonucci T; Bertani L; Costa F; Privitera G; Tolusso B; Di Mario C; Albano E; Tapete G; Gremese E; Papa A; Gasbarrini A; Rapaccini GL; Armuzzi A
United European Gastroenterol J; 2019 Nov; 7(9):1189-1197. PubMed ID: 31700632
[TBL] [Abstract][Full Text] [Related]
13. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
Schreiber S; Dignass A; Peyrin-Biroulet L; Hather G; Demuth D; Mosli M; Curtis R; Khalid JM; Loftus EV
J Gastroenterol; 2018 Sep; 53(9):1048-1064. PubMed ID: 29869016
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.
Yarur AJ; Bruss A; Naik S; Beniwal-Patel P; Fox C; Jain A; Berens B; Patel A; Ungaro R; Bahur B; Dubinsky M; Stein DJ
Dig Dis Sci; 2019 Jun; 64(6):1651-1659. PubMed ID: 30835029
[TBL] [Abstract][Full Text] [Related]
15. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
[TBL] [Abstract][Full Text] [Related]
16. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A; Straatmijer T; Duijvestein M; Sales A; Levran A; van Schaik F; Maljaars J; Gecse K; Ponsioen C; Grootjans J; Hanzel J; Tack G; Jansen J; Hoentjen F; de Boer N; van der Marel S; Dijkstra G; Oldenburg B; Löwenberg M; van der Meulen A; D Haens G;
Aliment Pharmacol Ther; 2022 Sep; 56(6):1044-1054. PubMed ID: 35869807
[TBL] [Abstract][Full Text] [Related]
18. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
Dragoni G; Bagnoli S; Le Grazie M; Campani C; Rogai F; Manetti N; Bensi C; Macrì G; Galli A; Milla M
J Dig Dis; 2019 May; 20(5):235-242. PubMed ID: 30927309
[TBL] [Abstract][Full Text] [Related]
20. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
Yarur AJ; Deepak P; Vande Casteele N; Battat R; Jain A; Okada L; Osterman M; Regueiro M
Dig Dis Sci; 2021 Oct; 66(10):3563-3569. PubMed ID: 33089483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]